Article
A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2020
Kalbasi Anusha, Kamrava Mitchell, Chu Fang-I, Telesca Donatello, Van Dams Ritchell, Yang Yingli, Ruan Dan, Nelson Scott D, Dry Sarah M, Hernandez Jackie, Chmielowski Bartosz, Singh Arun S, Bukata Susan V, Bernthal Nicholas M, Steinberg Michael L, Weidhaas Joanne B, Eilber Fritz C
Abstract excerpt
PURPOSE: In a single-institution phase II study, we evaluated the safety of a 5-day dose-equivalent neoadjuvant radiotherapy (RT) regimen for high-risk primary soft tissue sarcoma. PATIENTS AND METHODS: Patients received neoadjuvant RT alone (30 Gy in five fractions) to the primary tumor with standard margins. The primary endpoint was grade ≥2 late-radiation toxicity. Major wound complications, local recurrences,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.